Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 269-276

  Koizumi, Keiichi ^a   Kato, Shinichiro ^a   Sakurai, Hiroaki ^a   Hashimoto, Isaya ^a   Yasumoto, Kazuo ^b   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

CXCR4; Gastric cancer; MTOR; Peritoneal carcinomatosis; Review

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR; EVEROLIMUS; MOZOBIL TM; PLERIXAFOR; RAPAMYCIN; RIDAFOROLIMUS; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTHRALGIA; ARTICLE; BIOLOGICAL FUNCTIONS; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CELL PROLIFERATION; DIARRHEA; DISTANT METASTASIS; DIZZINESS; FATIGUE; FLATULENCE; GLIOBLASTOMA; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INJECTION SITE REACTION; INSOMNIA; KIDNEY CANCER; LEUKOCYTE; LUNG METASTASIS; LYMPHOMA; METASTASIS; MULTICENTER STUDY (TOPIC); NAUSEA; OVERALL SURVIVAL; PERITONEAL CAVITY; PERITONEUM METASTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOMA; STOMACH CANCER; STOMACH CARCINOMA; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; VOMITING; ANIMAL; CARCINOMA; DRUG ANTAGONISM; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERITONEUM TUMOR; REVIEW; SIGNAL TRANSDUCTION; STOMACH TUMOR;

ANIMALS; CARCINOMA; CHEMOKINE CXCL12; HUMANS; MOLECULAR TARGETED THERAPY; PERITONEAL NEOPLASMS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84866098504     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s267     Document Type: Article

References (47)

1. O Yoshie, T Imai, H Nomiyama: Novel lymphocytespecific CC chemokines and their receptors. J Leukoc Biol, 62, 634-644 (1997)
2. O Yoshie: Immune chemokines and their receptors: the key elements in the genesis, homeostasis and function of the immune system. Springer Semin Immunopathol, 22, 371-291 (2000)
3. A Zlotnik: Chemokines and cancer. Int J Cancer, 119, 2026-9 (2006)
4. A Zlotnik, O. Yoshie, H Nomiyama: The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol, 7, 243 (2006)
5. Y Maru: Logical structures extracted from metastasis experiments. Cancer Sci, 100, 2006-13 (2009)
6. A Muller, B Homey, H Soto, N Ge, D Catron, M. E Buchanan, T McClanahan, E Murphy, W Yuan, S. N Wagner, J. L Barrera, A Mohar, E Verastegui, A Zlotnik: Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50-56 (2001)
7. K Yasumoto, K Koizumi, A Kawashima, Y Saitoh, Y Arita, K Shinohara, T Minami, T Nakayama, H Sakurai, Y Takahashi, O Yoshie, I Saiki: Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res, 66, 2181-2187 (2006)
8. E.S Nakamura, K Koizumi, M Kobayashi, Y Saitoh, Y Arita, T Nakayama, H Sakurai, O Yoshie, I Saiki: RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis, 23, 9-18 (2006)
9. A Mantovani, B Savino, M Locati, L Zammataro, P Allavena, R Bonecchi: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev, 21, 27-39 (2010)
10. T Ishida, T Ishii, A Inagaki, H Yano, S Kusumoto, Ri, H Komatsu, S Iida, H Inagaki, R Ueda: The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia, 20, 2162-2168 (2006)
11. T Ishida, S Iida, Y Akatsuka, T Ishii, M Miyazaki, H Komatsu, H Inagaki, N Okada, T Fujita, K Shitara, Akinaga, T Takahashi, A Utsunomiya, R Ueda: The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res, 10, 7529-7539 (2004)
12. R Niwa, E Shoji-Hosaka, M Sakurada, T Shinkawa, K Uchida, K Nakamura, K Matsushima, R Ueda, N Hanai, K Shitara: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res, 64, 2127-2133 (2004)
13. A Zlotnik: New insights on the role of CXCR4 in cancer metastasis. J Pathol, 215, 211-213 (2008)
14. T Nagasawa, K Tachibana, T Kishimoto: A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol, 10, 179-185 (1998)
15. M Kato, J Kitayama, S Kazama, H Nagawa: Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res, 5, 144-150 (2003)
16. R.S Taichman, C Cooper, E.T Keller, K.J Pienta, N.S Taichman, L.K McCauley: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 62, 1832-1837 (2002)
17. K Oonakahara, W Matsuyama, I Higashimoto, M Kawabata, K Arimura, M Osame: Stromal-derived factor- 1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol, 30, 671-7 (2004)
18. C.J Scotton, J. L Wilson, K Scott, G Stamp, G.D Wilbanks, S Fricker, G Bridger, F.R Balkwill: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res, 62, 5930-5938 (2002)
19. D Saur, B Seidler, G Schneider, H Algul, R Beck, R Senekowitsch- Schmidtke, M Schwaiger, R.M Schmid: CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology, 129, 1237-1250 (2005)
20. S Scala, A Ottaiano, P.A Ascierto, M Cavalli, E Simeone, P Giuliano, M Napolitano, R Franco, G Botti, G Castello: Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res, 11, 1835-1841 (2005)
21. H.V Russell, J Hicks, M.F Okcu, J.G Nuchtern: CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg, 39, 1506-1511 (2004)
22. J.T Kaifi, J. E.F Yekebas, P Schurr, D Obonyo, R Wachowiak, P Busch, A Heinecke, K Pantel, J.R Izbicki: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst, 97, 1840-1847 (2005)
23. J Kim, H Takeuchi, S.T Lam, R.R Turner, H.J Wang, C Kuo, L Foshag, A.J Bilchik, D.S Hoon: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol, 23, 2744-2753 (2005)
24. Y Oda, H Yamamoto, S Tamiya, S Matsuda, K Tanaka, R Yokoyama, Y Iwamoto, M Tsuneyoshi: CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol, 19, 738-745 (2006)
25. J Pan, J Mestas, M.D Burdick, R.J Phillips, G.V Thomas, K Reckamp, J.A Belperio, R.M Strieter: Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer, 5, 56 (2006)
26. J.P Spano, F Andre, L Morat, L Sabatier, B Besse, C Combadiere, Deterre, A Martin, J Azorin, D Valeyre, D Khayat, T Le Chevalier, J.C Soria: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol, 15, 613-677 (2004)
27. Y.M Li, Y Pan, Y Wei, X Cheng, B.P Zhou, M Tan, X Zhou, W Xia, G.N Hortobagyi, D Yu, M.C Hung: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6, 459-469 (2004)
28. E Bando, Y Yonemura, Y Takeshita, K Taniguchi, T Yasui, Y Yoshimitsu, S Fushida, T Fujimura, G Nishimura, K Miwa: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg, 178, 256-262 (1999)
29. I Duarte, O. Llanos: Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol, 12, 237-242 (1981)
30. Y Maehara, S Moriguchi, Y Kakeji, S Kohnoe, D Korenaga, M Haraguchi, K Sugimachi: Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery, 110, 820-823 (1991)
31. I Takahashi, T Matsusaka, T Onohara, T Nishizaki, T Ishikawa, H Tashiro, K Wakasugi, K Kume, Y Maehara, K Sugimachi: Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology, 47, 1485-1488 (2000)
32. T Murakami, W Maki, A.R Cardones, H Fang, A Tun Kyi, F.O Nestle, S.T Hwang: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res, 62, 7328-7334 (2002)
33. Y.X Sun, A Schneider, Y Jung, J Wang, J Dai, J Wang, K Cook, N.I Osman, A J. Koh-Paige, H Shim, K.J Pienta, E.T Keller, L.K McCauley, R.S Taichman: Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res, 20, 318-229 (2005)
34. De Clercq, E: Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol, 57, 833-839 (2000)
35. De Clercq, E: The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil) Biochem Pharmacol, 77, 1655-1664 (2009)
36. M Brave, A Farrell, L.S Ching, T.P Ocheltree, S Miksinski, S.L Lee, H Sabe, J Fourie, C Tornoe, B Booth, W Yuan, K He, R Justice, R Pazdur. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology, 78, 282-288 (2010)
37. A Yamada, N Saito, S Kameoka, M Kobayashi: Clinical significance of epidermal growth factor (EGF) expression in gastric cancer. Hepatogastroenterology, 54, 1049-52 (2007)
38. M Yashiro, Y.S Chung, T Inoue, S Nishimura, T Matsuoka, T Fujihara, M Sowa: Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer, 67, 289-293 (1996)
39. M Kamiyama, Y Ichikawa, T Ishikawa, T Chishima, S Hasegawa, Y Hamaguchi, Y Nagashima, Y Miyagi, M Mitsuhashi, D Hyndman, R.M Hoffman, S Ohki, H Shimada: VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice. Cancer Gene Ther, 9, 197-201 (2002)
40. Lo, S. S., C. W. Wu, C. W. Chi, A. F. Li, J. H. Chen & W. Y. Lui: High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis. Hepatogastroenterology, 52, 1902-4 (2005)
41. V Stambolic, J.R Woodgett: Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol, 16, 461-466 (2006)
42. I Hashimoto, K Koizumi, M Tatematsu, T Minami, S Cho, N Takeno, A Nakashima, H Sakurai, S Saito, K Tsukada, I. Saiki: Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer, 44, 1022-1029 (2008)
43. G.J Brunn, C.C Hudson, A Sekulic, J.M Williams, H Hosoi, P.J Houghton, J.C Lawrence, Jr., R.T Abraham: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science, 277, 99-101 (1997)
44. X Wan, L.J Helman: The biology behind mTOR inhibition in sarcoma. Oncologist, 12, 1007-1018 (2007)
45. M Nishimura, M.S. Shin, P Singhirunnusorn, S Suzuki, M Kawanishi, K Koizumi, I Saiki, H. Sakurai: TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol, 29, 5529-2539 (2009)
46. M.S Shin, P Shinghirunnusorn, Y Sugishima, M Nishimura, S Suzuki, K Koizumi, I Saiki, H Sakurai: Cross interference with TNF-alpha-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim Biophys Acta, 1793, 1156-1164 (2009)
47. H Azim, H.A Azim, Jr., B Escudier: Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol, 4, 269-280 (2010)